Evidence map›Paper›PMID 32201749›Full record

ArticleChem2020

Metallotexaphyrins as MRI-Active Catalytic Antioxidants for Neurodegenerative Disease: A Study on Alzheimer's Disease.

James T Brewster, Gregory D Thiabaud, Peter Harvey, Hadiqa Zafar, James F Reuther, Simone Dell'Acqua, Rachel M Johnson, Harrison D Root, Pedro Metola, Alan Jasanoff and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Chem, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 28 citations in OpenAlex.

  1. Design of bifunctional pyridinophane ligands as MnInorganic chemistry frontiers · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Crownphyrins: Metal-Mediated Transformations of the Porphyrin-Crown Ether Hybrids.Angewandte Chemie (International ed. in English) · 2022
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 4 countries.

James T BrewsterDepartment of Chemistry, the University of Texas at Austin, Austin, TX 78712-1224, USA.
Gregory D ThiabaudDepartment of Chemistry, the University of Texas at Austin, Austin, TX 78712-1224, USA.
Peter HarveyDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Hadiqa ZafarDepartment of Chemistry, the University of Texas at Austin, Austin, TX 78712-1224, USA.
James F ReutherDepartment of Chemistry, the University of Texas at Austin, Austin, TX 78712-1224, USA.
Simone Dell'AcquaDepartment of Chemistry, University of Pavia, Via Taramelli 12, 27100 Pavia, Italy.
Rachel M JohnsonAccelerated Research Initiative, University of Texas at Austin, Austin, TX 78712, USA.
Harrison D RootDepartment of Chemistry, the University of Texas at Austin, Austin, TX 78712-1224, USA.
Pedro MetolaAccelerated Research Initiative, University of Texas at Austin, Austin, TX 78712, USA.
Alan JasanoffDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Luigi CasellaDepartment of Chemistry, University of Pavia, Via Taramelli 12, 27100 Pavia, Italy.
Jonathan L SesslerDepartment of Chemistry, the University of Texas at Austin, Austin, TX 78712-1224, USA.
The University of Texas at Austin · USUniversity of Pavia · ITMassachusetts Institute of Technology · USShanghai University · CNUniversity of Massachusetts Lowell · USUniversity of Nottingham · GB

Funding

Enhancing and expanding the CGC Strain CollectionP40OD010440 · OD · UNIVERSITY OF MINNESOTA · PI Aric L Daul, Ann E. Rougvie · 2012 to 2026
$7.5M
Biomedical Applications of Expanded Porphyrins: Development of Gold-Texaphyrin ConjugatesR01CA068682 · NCI · UNIVERSITY OF TEXAS AUSTIN · PI Esther Y. Maier, Emily L Que · 1995 to 2026
$7.4M
Intracellular calcium sensing with molecular fMRIUF1NS107712 · NINDS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI JASANOFF, ALAN · 2018 to 2018
$1.4M
Bruker AVANCE III HD 500 MHz NMRS10OD021508 · OD · UNIVERSITY OF TEXAS AT AUSTIN · PI SESSLER, JONATHAN L · 2016 to 2016
$529k
NCI NIH HHS R01 CA068682NIH HHS P40 OD010440NIH HHS S10 OD021508NINDS NIH HHS UF1 NS107712Wellcome Trust
6 · The paper itself

Abstract

The complex etiology of neurodegeneration continues to stifle efforts to develop effective therapeutics. New agents elucidating key pathways causing neurodegeneration might serve to increase our understanding and potentially lead to improved treatments. Here, we demonstrate that a water-soluble manganese(II) texaphyrin (MMn) is a suitable magnetic resonance imaging (MRI) contrast agent for detecting larger amyloid beta constructs. The imaging potential of MMn was inferred on the basis of

Indexed as

Alzheimer’s diseaseamyloid aggregationamyloid betaamyloid beta modifications by ROS and RNSC. elegans AD modelsexpanded porphyrinmetalloantioxidantMRIneurodegenerationtexaphyrin

Identifiers

PMID32201749
PMCPMC7074011
OpenAlexW2998919204

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.